'The more you link, the more you risk …' - a focus group study exploring views about data linkage for pharmacovigilance.

AIMS The aim of this study was to assess opinions of frontline healthcare professionals on the linking of routinely collected national (Scottish) paediatric data for the purpose of identifying earlier signals of adverse drug reactions. METHODS Stratified purposive sampling led to profession-specific focus groups with pharmacists, nurses and medical doctors from primary and secondary care in different Scottish Health Boards. A topic guide was used to explore the proposed data linkage of routinely collected paediatric data. Discussions were audio recorded and transcribed verbatim. Transcripts were analysed using a framework approach to identify themes. Ethical approval was obtained from the North of Scotland Research Ethics Service. RESULTS Six focus groups were conducted in 2011 with 22 participants. Views of the proposed data linkage were generally positive. Several issues were identified, including lack of clarity on data ownership and concerns about diversion of funding. Identified issues were at a practical rather than a strategic level. CONCLUSIONS This study identified that professional stakeholder groups are likely to find linkage of paediatric patient data acceptable. Barriers identified could be addressed. Focus group participants commented on the importance of informing patients and members of the public about the benefits of linking healthcare data. These findings clarify the steps that should be taken to ensure the acceptability of data linkage for pharmacovigilance.

[1]  J. Haughney,et al.  Linked health data for pharmacovigilance in children: perceived legal and ethical issues for stakeholders and data guardians , 2014, BMJ Open.

[2]  A. Blenkinsopp,et al.  Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. , 2007, British journal of clinical pharmacology.

[3]  H Corns,et al.  Unlicensed and off label prescribing of drugs in general practice , 2000, Archives of disease in childhood.

[4]  J. Cappelleri,et al.  A systematic review on the application of pharmacoepidemiology in assessing prescription drug-related adverse events in pediatrics , 2007, Current medical research and opinion.

[5]  C. Bond,et al.  Monitoring adverse drug reactions in children using community pharmacies: a pilot study. , 2005, British journal of clinical pharmacology.

[6]  K. Verhamme,et al.  Databases for pediatric medicine research in Europe—assessment and critical appraisal , 2008, Pharmacoepidemiology and drug safety.

[7]  Peter J. Helms,et al.  Off-label prescribing to children in primary care: retrospective observational study , 2004, European Journal of Clinical Pharmacology.

[8]  G. Glover A comprehensive clinical database for mental health care in England , 2000, Social Psychiatry and Psychiatric Epidemiology.

[9]  I. Choonara,et al.  Surveillance for fatal suspected adverse drug reactions in the UK , 2002, Archives of disease in childhood.

[10]  Maurizio Bonati,et al.  Survey of unlicensed and off label drug use in paediatric wards in European countries , 2000, BMJ : British Medical Journal.

[11]  D. Stewart,et al.  Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey. , 2007, British journal of clinical pharmacology.

[12]  J. Kitzinger,et al.  Qualitative Research: Introducing focus groups , 1995 .

[13]  S. Conroy,et al.  Unlicensed and Off-Label Drug Use in Children , 2002, Drug safety.

[14]  P Impicciatore,et al.  Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. , 2001, British journal of clinical pharmacology.

[15]  I. Choonara,et al.  Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective study , 1999, Acta paediatrica.

[16]  J. Ritchie,et al.  Qualitative Research Practice: A Guide for Social Science Students and Researchers , 2013 .